People who received Pfizer-BioNTech vaccines may get as much benefit from a Johnson & Johnson booster shot as a Pfizer one. That’s the finding of a small study released on Sunday.

Researchers at the Beth Israel Deaconess Medical Center in Boston studied 65 people who had received two shots of the Pfizer vaccine. Six months after the second dose, the researchers gave 24 of the volunteers a third dose of the Pfizer vaccine and gave 41 the Johnson & Johnson shot. (The study was funded in part by Johnson & Johnson and has not yet been published in a scientific journal.)

Continue reading “A J.&J. booster works well for people who had Pfizer-BioNTech doses originally, a study finds.” →

People looking for a booster shot of a Covid-19 vaccine probably don’t need to fret about what brand it is: Many combinations of shots are likely to provide strong protection, according to a large new study.

In a comparison of seven different vaccine brands, British researchers found that most of them prompted a strong immune response, with the mRNA shots from Moderna and Pfizer-BioNTech eliciting the largest responses. The study was published on Thursday in The Lancet.

Continue reading “Most Covid Vaccines Will Work as Boosters, Study Suggests” →

A federal advisory committee on Tuesday voted to recommend that the government for the first time authorize the use of an antiviral pill to combat the worst effects of Covid-19.

The advisory committee, in a surprisingly narrow 13-to-10 vote, endorsed the pill from Merck, while public health officials worldwide raced to buttress their defenses against the newly emerging Omicron variant of the coronavirus.

The Merck treatment, known as molnupiravir, has been shown to modestly reduce the risk of hospitalization and death from Covid. The pill could be authorized for use in the United States within days and available to patients within weeks.

Continue reading “Merck’s Covid Treatment Pill Wins Blessing of F.D.A. Panel” →

Scientific experts at the World Health Organization warned on Friday that a new coronavirus variant discovered in southern Africa was a “variant of concern,” the most serious category the agency uses for such tracking.

The designation, announced after an emergency meeting of the health body, is reserved for dangerous variants that may spread quickly, cause severe disease or decrease the effectiveness of vaccines or treatments. The last coronavirus variant to receive this label was Delta, which took off this summer and now accounts for virtually all Covid cases in the United States.

The W.H.O. said the new version, named Omicron, carries a number of genetic mutations that may allow it to spread quickly, perhaps even among the vaccinated.

Continue reading “New Virus Variant Stokes Concern but Vaccines Still Likely to Work” →